

Richard F Bergstrom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10916160/publications.pdf>

Version: 2024-02-01

29
papers

2,023
citations

279798

23
h-index

477307

29
g-index

29
all docs

29
docs citations

29
times ranked

1399
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials. <i>Clinical and Translational Science</i> , 2021, 14, 1864-1874.	3.1	5
2	Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1200-1208.	4.7	3
3	Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques. <i>Clinical and Translational Science</i> , 2019, 12, 519-528.	3.1	37
4	Pharmacokinetics of olanzapine long-acting injection. <i>International Clinical Psychopharmacology</i> , 2014, 29, 299-312.	1.7	37
5	Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. <i>BMC Psychiatry</i> , 2010, 10, 45.	2.6	76
6	Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 181-189.	7.2	181
7	Oral Olanzapine Disposition in Adolescents with Schizophrenia or Bipolar I Disorder. <i>Paediatric Drugs</i> , 2010, 12, 201-211.	3.1	20
8	Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 278-283.	1.4	75
9	Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 184-187.	2.4	24
10	Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients With Childhood-Onset Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 220-225.	1.4	64
11	Olanzapine. <i>Clinical Pharmacokinetics</i> , 1999, 37, 177-193.	3.5	460
12	Fluoxetine in Depressed Patients on Dialysis. <i>International Journal of Psychiatry in Medicine</i> , 1997, 27, 71-80.	1.8	114
13	The effect of sertraline on the pharmacokinetics of desipramine and imipramine. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 145-156.	4.7	63
14	Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 643-651.	4.7	36
15	Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 239-248.	4.7	171
16	Secretion of nizatidine into human breast milk after single and multiple doses. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 724-730.	4.7	25
17	Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 499-503.	4.7	8
18	Fluoxetine disposition and elimination in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 353-359.	4.7	69

#	ARTICLE	IF	CITATIONS
19	The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 412-419.	4.7	117
20	Nizatidine disposition in subjects with normal and impaired renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 688-695.	4.7	25
21	Nizatidine, an H ₂ -Receptor Antagonist: Disposition and Safety in the Elderly. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 618-624.	2.0	19
22	Absorption studies of the H ₂ -blocker nizatidine. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 514-520.	4.7	29
23	Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 658-664.	4.7	38
24	Intravenous nizatidine kinetics and acid suppression. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 162-165.	4.7	40
25	Fluoxetine kinetics and protein binding in normal and impaired renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 36, 138-144.	4.7	104
26	High-performance liquid chromatographic determination of penicillamine in whole blood, plasma, and urine. <i>Biomedical Applications</i> , 1981, 222, 445-452.	1.7	70
27	Penicillamine kinetics in normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 404-413.	4.7	67
28	The pharmacokinetics of penicillamine in a female mongrel dog. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 603-621.	0.6	16
29	The in vitro loss of penicillamine in plasma, albumin solutions, and whole blood: Implications for pharmacokinetic studies of penicillamine. <i>Life Sciences</i> , 1980, 27, 189-198.	4.3	30